The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention


Based on data regarding the effect of colchicine on the inflammasome NLP3 and microtubule formation and associations thereof with the pathogenetic cycle of SARS-COV-2, the question arises whether colchicine, administered in a relatively low dose, could potentially have an effect the patients' clinical course by limiting the myocardial necrosis and pneumonia development in the context of COVID-19. If present, this effect would be attributed to its potential to inhibit inflammasome and (less probably) to the process of SARS-CoV-2 endocytosis in myocardial and endothelial respiratory cells.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 31, 2020


  • Drug: Colchicine
    • Low-dose colchicine treatment, 0.5 mg bid
  • Drug: Standard treatment
    • Standard treatment

Arms, Groups and Cohorts

  • Experimental: Intervention
    • Colchicine, on top of standard treatment
  • Active Comparator: Control
    • Standard treatment, including all medications recommedned by the National Public Health Organization

Clinical Trial Outcome Measures

Primary Measures

  • Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&D committee
    • Time Frame: 3 weeks
    • Time to clinical deterioration (2 levels in the WHO R&D Blueprint scale)
  • Maximal concentration of cardiac troponin
    • Time Frame: 10 days
    • Maximal concentration of high-sensitivity cardiac troponin

Participating in This Clinical Trial

Inclusion Criteria

Patients >18 years old with laboratory confirmed SARS-CoV-2 infection (RT PCR) AND body temperature >37.5 degrees centigrade AND at least two of: i. sustained coughing, ii. sustained throat pain, iii. anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg.

Exclusion Criteria

  • pregnancy, lactation;
  • known hypersensitivity to colchicine
  • known hepatic failure
  • eGFR<20 ml/min
  • clinical estimation that the patient will require mechanical respiratory support in less than 24 hours
  • any clinical estimation of the attending physician under which the patient shall be excluded
  • QTc > 450 msec (colchicine is not known to significantly prolong QTc, but may interact with other medications which prolong QTc).
  • participation in another clinical trial
  • under colchicine treatment for other indications
  • patient who is not likely to comply to study procedures

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • National and Kapodistrian University of Athens
  • Provider of Information About this Clinical Study
    • Principal Investigator: Spyridon Deftereos, Professor of Cardiology – National and Kapodistrian University of Athens
  • Overall Contact(s)
    • Spyridon Deftereos, 00306944699901,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.